Recombinant Human CXCL17 Protein，His

CXCL17, a member of the CXC chemokine family, has garnered attention due to its unique structural and functional characteristics. Initially identified for its role in immune response, CXCL17 is primarily expressed by various cell types, including epithelial cells and macrophages, and plays a significant role in mediating the recruitment of immune cells to sites of infection or inflammation. Research has shown that CXCL17 is involved in various pathological processes, including cancer progression, autoimmune diseases, and chronic inflammatory conditions. Its ability to bind to the chemokine receptor CXCR8 suggests a crucial role in modulating immune responses. Recent studies have focused on the production of recombinant CXCL17 protein to better understand its biological functions and potential therapeutic applications. By employing recombinant DNA technology, researchers aim to generate a stable supply of CXCL17 for in vitro and in vivo studies. These investigations seek to elucidate the signaling pathways activated by CXCL17, its role in tumor microenvironments, and its potential as a biomarker for disease progression. Additionally, understanding the structure-activity relationship of CXCL17 could pave the way for novel drug development aimed at manipulating its activity for therapeutic benefits. Given the increasing recognition of chemokines in the context of cancer immunotherapy and other disease treatments, the study of CXCL17 and its recombinant protein will likely contribute important insights into the intricate interplay between the immune system and disease pathogenesis.